Recent Advances in Biodistribution, Preclinical and Clinical Applications of Radiolabelled Iodine
Authors:
- Khaled SolimanKSKhaled Soliman
- Ahmed AleneziAAAhmed Alenezi
- Abdullah AlrushoudAAAbdullah Alrushoud
- Salman AltimyatSASalman Altimyat
- Mousa BakkariMBMousa Bakkari
- Hanaa AlshikhHAHanaa Alshikh
- Turki AlruwailiTATurki Alruwaili
Open Access
- 15 June 2022
- book chapter
- Published by IntechOpen
Abstract
Adequate understanding of radiopharmaceutical distribution in the body of the patient has both spatial and temporal characteristics and they are the key factor to consider when planning successful radio pharmaceutical therapy, because they are an integral part of the radiation dosimetry calculations of any proposed personalized treatment. In this chapter we will focus on radioiodine therapy for thyroid cancer patients since it is a widely known practice in clinical oncology. Factors affecting the radioiodine organs’ distribution will be examined in sufficient details using the available published research in the scientific literature. The literature will be reviewed extensively and summarized in this chapter. Another aim is to provide the medical practitioners with a quick reference guide to this clinically important area of expertise; often mastered by medical physicists with background in radiation physics, mathematics and medical imaging analysis. This chapter will cover recent advances in the area of radioiodine biodistribution modeling with applications in preclinical and clinical studies.Keywords
This publication has 23 references indexed in Scilit:
- Mesenchymal Stem Cell–Mediated, Tumor Stroma–Targeted Radioiodine Therapy of Metastatic Colon Cancer Using the Sodium Iodide Symporter as Theranostic GeneJournal of Nuclear Medicine, 2015
- Thyroid Circadian TimingJournal of Biological Rhythms, 2014
- Biodistribution and Dosimetry of Free 211 At, 125 I − and 131 I − in RatsCancer Biotherapy and Radiopharmaceuticals, 2013
- The role of 131I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancerHead & Neck, 2010
- MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of NomenclatureJournal of Nuclear Medicine, 2009
- The biodistribution of radioiodine on posttherapy iodine-131 scans in thyroid cancer patients with chronic renal failureNuclear Medicine Communications, 2008
- Normal Organ Radiation Dosimetry and Associated Uncertainties in Nuclear Medicine, with Emphasis on Iodine-131Radiation Research, 2006
- The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomabSeminars in Oncology, 2003
- ICRP Publication 30, Part 1, 1979Annals of the ICRP, 1979